Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Alpha-1-antitrypsin; total

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 82103 refers to the measurement of total Alpha-1-antitrypsin (A1A) levels in the blood. Alpha-1-antitrypsin is a crucial protein synthesized in the liver, which plays a significant role as a serum protease inhibitor. This protein is essential for protecting various organs, particularly the lungs, from damage caused by proteolytic enzymes, such as elastase, which can lead to tissue destruction. In the absence of adequate levels of Alpha-1-antitrypsin, which is often due to genetic factors, individuals may experience significant organ damage, particularly in the lungs, resulting in conditions like early onset emphysema. The measurement of Alpha-1-antitrypsin levels is particularly important in clinical settings for diagnosing the underlying causes of certain symptoms, such as persistent jaundice or other indications of liver dysfunction. The testing process involves obtaining a blood sample through a procedure known as venipuncture, which is reported separately. The serum obtained from the blood sample is then analyzed using an immunoturbidimetric technique to determine the total levels of Alpha-1-antitrypsin present. This test is often a preliminary step, and if the results indicate lower than normal levels of Alpha-1-antitrypsin, further testing may be warranted to assess the phenotype of the protein, which can provide additional insights into the patient's condition and guide treatment options.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The Alpha-1-antitrypsin total test (CPT® Code 82103) is indicated for several clinical scenarios, particularly when evaluating patients for specific symptoms or conditions. The following are the primary indications for performing this test:

  • Early Onset Emphysema - The test is performed to help diagnose the cause of early onset emphysema, which may be linked to deficiencies in Alpha-1-antitrypsin.
  • Persistent Jaundice - It is indicated in patients exhibiting persistent jaundice, which may suggest liver dysfunction.
  • Liver Dysfunction Symptoms - The test is also utilized in the evaluation of other symptoms associated with liver dysfunction, aiding in the diagnosis of potential underlying conditions.

2. Procedure

The procedure for measuring total Alpha-1-antitrypsin levels involves several key steps, which are outlined below:

  • Step 1: Patient Preparation - Prior to the blood draw, the patient may be instructed to follow specific guidelines, such as fasting or avoiding certain medications, although these instructions are not explicitly detailed in the provided data.
  • Step 2: Venipuncture - A qualified healthcare professional performs a venipuncture to obtain a blood sample. This involves inserting a needle into a vein, typically in the arm, to collect the necessary blood volume for testing. The venipuncture is reported separately from the Alpha-1-antitrypsin test.
  • Step 3: Serum Separation - After the blood sample is collected, it is processed to separate the serum from the cellular components. This step is crucial as the serum contains the Alpha-1-antitrypsin that will be measured.
  • Step 4: Testing - The serum is then subjected to analysis using the immunoturbidimetric technique. This method allows for the quantification of total Alpha-1-antitrypsin levels in the serum, providing essential data for clinical evaluation.

3. Post-Procedure

After the procedure, patients may experience minor discomfort at the venipuncture site, which typically resolves quickly. There are no specific post-procedure care instructions provided in the data; however, patients are generally advised to keep the site clean and dry. Results from the Alpha-1-antitrypsin test will be interpreted by the healthcare provider, who may recommend further testing or treatment based on the findings. If the total levels are found to be lower than normal, additional phenotype testing may be indicated to assess the type of Alpha-1-antitrypsin present in the blood.

Short Descr ALPHA-1-ANTITRYPSIN TOTAL
Medium Descr ALPHA-1-ANTITRYPSIN TOTAL
Long Descr Alpha-1-antitrypsin; total
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 233 - Laboratory - Chemistry and Hematology
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
Q4 Service for ordering/referring physician qualifies as a service exemption
GY Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
GA Waiver of liability statement issued as required by payer policy, individual case
26 Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.
76 Repeat procedure or service by same physician or other qualified health care professional: it may be necessary to indicate that a procedure or service was repeated by the same physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 76 to the repeated procedure or service. note: this modifier should not be appended to an e/m service.
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
GW Service not related to the hospice patient's terminal condition
Q1 Routine clinical service provided in a clinical research study that is in an approved clinical research study
XU Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service
Date
Action
Notes
2011-01-01 Changed Short description changed.
1993-01-01 Added First appearance in code book in 1993.
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"